Adaptimmune Therapeutics plc (MUN:473A)

Adaptimmune Therapeutics Revenue

Adaptimmune Therapeutics had revenue of $13.68M USD in the quarter ending June 30, 2025, a decrease of -89.33%. This brings the company's revenue in the last twelve months to $65.09M, down -53.99% year-over-year. In the year 2024, Adaptimmune Therapeutics had annual revenue of $178.03M with 195.34% growth.

• Revenue (ttm): $65.09M
• Revenue Growth: -53.99%
• P/S Ratio: 0.08
• Revenue / Employee: $128.63K
• Employees: 506
• Market Cap: 4.53M EUR

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	178.03M	117.75M	195.34%
Dec 31, 2023	60.28M	33.13M	122.05%
Dec 31, 2022	27.15M	21.00M	341.50%
Dec 31, 2021	6.15M	2.19M	55.36%
Dec 31, 2020	3.96M	2.84M	252.76%

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 13, 2026

Data Sources Report a data error